Capital Research Global Investors Grows Stock Holdings in Integer Holdings Co. (NYSE:ITGR)

Capital Research Global Investors grew its stake in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 16.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,410,803 shares of the medical equipment provider's stock after acquiring an additional 194,895 shares during the period. Capital Research Global Investors owned 4.21% of Integer worth $186,960,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Integer in the 4th quarter valued at $38,073,000. Artisan Partners Limited Partnership bought a new stake in Integer during the fourth quarter valued at $22,775,000. Laurus Investment Counsel Inc. bought a new stake in Integer during the fourth quarter valued at $5,422,000. New York State Common Retirement Fund increased its stake in Integer by 20.9% in the 4th quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider's stock worth $30,820,000 after acquiring an additional 40,158 shares during the last quarter. Finally, Wealthfront Advisers LLC bought a new position in Integer in the 4th quarter worth about $4,754,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. StockNews.com lowered Integer from a "hold" rating to a "sell" rating in a report on Friday. Raymond James increased their price target on shares of Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a report on Friday. Oppenheimer downgraded shares of Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Truist Financial set a $150.00 target price on Integer in a research note on Friday. Finally, Benchmark dropped their price target on Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research note on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Integer has a consensus rating of "Moderate Buy" and an average price target of $145.56.

Integer Trading Up 1.6 %

Shares of ITGR traded up $1.93 during trading hours on Friday, reaching $123.39. 450,999 shares of the company traded hands, compared to its average volume of 346,447. Integer Holdings Co. has a 12 month low of $104.93 and a 12 month high of $146.36. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The company's fifty day moving average price is $119.58 and its two-hundred day moving average price is $130.26. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of 36.72, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $437.39 million for the quarter, compared to analysts' expectations of $428.51 million. Equities research analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.